Mycotopia Therapies Inc
Mycotopia Therapies, Inc. focuses on psychedelics for the treatment of mental health issues. It provides psychedelic therapies for the treatment of post-traumatic stress disorder, palliative care, depression, and anxiety. The company is based in Miami, Florida. Mycotopia Therapies, Inc. is a subsidiary of EHAVE, Inc.
Mycotopia Therapies Inc (TPIA) - Net Assets
Latest net assets as of March 2025: $-3.39 Million USD
Based on the latest financial reports, Mycotopia Therapies Inc (TPIA) has net assets worth $-3.39 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.46 Million) and total liabilities ($4.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.39 Million |
| % of Total Assets | -233.01% |
| Annual Growth Rate | N/A |
| 5-Year Change | -847.29% |
| 10-Year Change | N/A |
| Growth Volatility | 135.63 |
Mycotopia Therapies Inc - Net Assets Trend (2016–2024)
This chart illustrates how Mycotopia Therapies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mycotopia Therapies Inc (2016–2024)
The table below shows the annual net assets of Mycotopia Therapies Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-3.39 Million | -67.38% |
| 2023-12-31 | $-2.03 Million | -127.56% |
| 2022-12-31 | $-891.35K | -362.14% |
| 2021-12-31 | $340.02K | -25.16% |
| 2020-12-31 | $454.31K | -30.31% |
| 2019-12-31 | $651.90K | +0.74% |
| 2018-12-31 | $647.10K | +13.08% |
| 2017-12-31 | $572.23K | +29.34% |
| 2016-12-31 | $442.41K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mycotopia Therapies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2689.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $39.99K | % |
| Other Components | $7.37 Million | % |
| Total Equity | $-3.39 Million | 100.00% |
Mycotopia Therapies Inc Competitors by Market Cap
The table below lists competitors of Mycotopia Therapies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SANKYO
MU:SOK
|
$113.87K |
|
HELMA Eigenheimbau Aktiengesellschaft
F:H5E
|
$113.89K |
|
KAYNE ANDE.MLP/M.I.DL-001
F:KA5
|
$113.91K |
|
KURWITU VENTURES LTD
XNAI:KVL
|
$113.94K |
|
Bankers Petroleum Ltd
TO:BNK
|
$113.70K |
|
Danske Invest Select Kommuner4
CO:DSIKOM4
|
$113.67K |
|
StoneCo Ltd. Reg.Sh. Cl.A DL-0
STU:0Q0
|
$113.66K |
|
Inhome Prime Properties SOCIMI S.A.
MC:YIPP
|
$113.59K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mycotopia Therapies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,028,310 to -3,394,968, a change of -1,366,658.
- Net loss of 1,848,275 reduced equity.
- Other factors increased equity by 481,617.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.85 Million | -54.44% |
| Other Changes | $481.62K | +14.19% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Mycotopia Therapies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.04 | $0.03 | x |
| 2017-12-31 | $0.05 | $0.03 | x |
| 2018-12-31 | $0.05 | $0.03 | x |
| 2019-12-31 | $0.05 | $0.03 | x |
| 2020-12-31 | $0.04 | $0.03 | x |
| 2021-12-31 | $0.03 | $0.03 | x |
| 2022-12-31 | $-0.06 | $0.03 | x |
| 2023-12-31 | $-0.14 | $0.03 | x |
| 2024-12-31 | $-0.25 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mycotopia Therapies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-97.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 16.35% | 0.56% | 10.81x | 2.68x | $28.11K |
| 2017 | 22.69% | 0.87% | 10.04x | 2.59x | $72.60K |
| 2018 | 9.46% | 0.00% | 0.00x | 2.32x | $-3.51K |
| 2019 | -2.68% | 0.00% | 0.00x | 1.86x | $-82.65K |
| 2020 | -53.31% | 0.00% | 0.00x | 1.00x | $-287.64K |
| 2021 | -874.17% | 0.00% | 0.00x | 3.74x | $-3.01 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.54 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-978.52K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.51 Million |
Industry Comparison
This section compares Mycotopia Therapies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mycotopia Therapies Inc (TPIA) | $-3.39 Million | 16.35% | N/A | $113.83K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |